The solid cancer targeting technology of Albatroz Therapeutics has been featured in A*STAR Research Highlights.
The therapeutic approach is based on the novel discovery by the A*STAR lab of Albatroz’s scientific founder Dr. Frederic Bard that glycosylation-driven extracellular matrix degradation is essential for tumor growth.
Albatroz Therapeutics Featured in A*STAR Research Highlights
